Volition Expands Supply Agreement with Fujifilm to Develop Feline Cancer Liquid Biopsy Test
VolitionRx Limited (NYSE: VNRX) has expanded its supply agreement with Fujifilm Vet Systems Co. Ltd to include the development of the Nu.Q® Vet Feline Test in Japan. This expansion aims to introduce what is expected to be the world's first affordable, blood-based liquid biopsy test for feline cancer, specifically targeting lymphoma. The move leverages Fujifilm's extensive network of approximately 11,000 veterinary facilities across Japan. Following the July 2024 launch of its canine version, Volition seeks to tap into the significant Japanese pet market, where there are nearly nine million cats. The test is intended for use on the Immunodiagnostic Systems (IDS) i10® automated analyzer platform.
Topics: Epigenetics Market Expansion Supply Agreement Veterinary Diagnostics